ACCESS / VALUE OF INNOVATION
Patient access to innovative PM technology and services is highly suboptimal and varies dramatically between EU member states and between regions in countries. The fact that a new medicine or innovative product can sometimes take as long as 20 years or more to get from bench to bedside is not only clearly undesirable but is arguably unacceptable in the 21st century.
This is not compatible with European social values and policies for cohesion. Keeping in mind the requisites on equity and (international) solidarity, a crucial challenge within the EU context is to make valuable innovations accessible to all EU citizens which requires solidarity within Member States and solidarity between Member States. Ideally, valuable Personalised Medicine technology should be accessible to patients in all markets and available there at an affordable price.